Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of EMD 121974 in treating
patients with solid tumors or lymphoma. Cilengitide (EMD 121974) may stop the growth of
cancer cells by stopping blood flow to the cancer